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Abstract: The undertreatment of acute pain is common in many health care settings. Insufficient 
management of acute pain may lead to poor patient outcomes and potentially life-threatening 
complications. Opioids provide relief of moderate to severe acute pain; however, therapy 
with pure µ-opioid agonists is often limited by the prevalence of side effects, particularly 
opioid-induced nausea and vomiting. Tapentadol is a novel, centrally acting analgesic with 
2 mechanisms of action, µ-opioid receptor agonism and norepinephrine reuptake inhibition. The 
analgesic effects of tapentadol are independent of metabolic activation and tapentadol has no 
active metabolites; therefore, in theory, tapentadol may be associated with a low potential for 
interindividual efficacy variations and drug–drug interactions. Previous phase 3 trials in patients 
with various types of moderate to severe acute pain have shown that tapentadol immediate 
release (IR; 50 to 100 mg every 4 to 6 hours) provides analgesia comparable to that provided 
by the pure µ-opioid agonist comparator, oxycodone HCl IR (10 or 15 mg every 4 to 6 hours), 
with a lower incidence of nausea, vomiting, and constipation. Findings suggest tapentadol may 
represent an improved treatment option for acute pain.
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Introduction
Appropriate management of acute pain remains a considerable challenge for health 
care providers. Unrelieved acute pain may cause anxiety, sleep disturbances, and 
demoralization and may interfere with mental activity and social interactions.1,2 Acute 
pain can also increase heart rate and blood pressure, suppress immune functioning, and 
reduce pulmonary function, leading to an increased risk of dangerous complications, 
including myocardial ischemia, deep vein thrombosis, pulmonary embolism, hypoxia, 
pneumonia, and stroke.2 In addition to these more severe adverse effects, uncontrolled 
acute pain is also associated with gastrointestinal effects, including the development 
of ileus, nausea, and vomiting.3
The psychologic and physiologic effects of uncontrolled acute pain can result in lon-
ger hospital stays and unscheduled readmissions following surgery.4,5 A retrospective 
analysis of the medical records of 20,817 patients who had undergone same-day 
surgery in 1999 found that pain was the most common reason that patients were 
hospitalized immediately after surgery or returned to the hospital within 30 days of 
surgery, accounting for 38% of unscheduled postoperative hospital admissions or 
readmissions.4 In addition, prolonged acute pain can cause sensitization of the central 
and peripheral nervous systems, leading to the development of chronic pain, which is 
often difficult and costly to treat.6–8Journal of Pain Research 2010:3 
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Although guidelines have been developed to improve 
acute pain management,9,10 pain relief remains suboptimal for 
many patients.11–16 Surveys conducted among patients who had 
undergone ambulatory surgery indicated that 30%15 to 40%12 
of patients experience moderate to severe pain following 
discharge. Among hospitalized patients who were receiving 
treatment in various medical wards14 or who had undergone 
surgery,11 the percentages were even higher, with 52%14 to 
80%11 of patients experiencing acute pain; of these patients, 
as many as 86% experienced moderate to extreme pain.11 The 
undertreatment of acute pain may result from several contrib-
uting factors related to patient care, such as infrequent pain 
assessments, underestimation of the severity of pain, concerns 
about side effects associated with analgesic treatment, and 
delays or dose reductions in the administration of analgesics by 
health care providers.13,14,17–20 In addition, patients may under-
report acute pain because of low expectations of pain relief and 
concerns about the adverse effects of analgesic treatment.19,21 
A 2004 survey of patients undergoing major abdominal surgery 
found that many patients were willing to sacrifice pain relief 
for a reduction in the severity of side effects.22
Current treatment options for the management of acute 
pain include opioid analgesics (eg, morphine, hydromorphone, 
and oxycodone) and nonopioid analgesics (eg, acetaminophen, 
acetylsalicylic acid, and nonsteroidal anti-inflammatory drugs 
[NSAIDs]).23 Most NSAIDs are limited by a therapeutic ceil-
ing and are appropriate for the relief of only mild to moderate 
pain.23 In addition, NSAIDs are contraindicated in patients with 
peptic ulcer disease, renal impairment, and any tendency for 
bleeding.24 Cyclooxygenase-2 (COX-2)-specific inhibitors do 
not impair platelet function and have an improved gastrointes-
tinal tolerability profile relative to other NSAIDs25; however, 
certain COX-2–specific inhibitors have been linked to an 
increase in the risk of cardiovascular side effects, including 
myocardial infarction.26
Opioids are typically used for the management of 
moderate to severe acute pain,27 but opioid use is limited 
by the occurrence of a range of side effects.28 Opioids exert 
their analgesic effects primarily through agonistic interac-
tions with µ-opioid receptors in neurons in the pain path-
way, which lead to a reduction in neurotransmitter release 
and associated pain.29 However, the agonistic interactions 
responsible for opioid activity are not limited to neurons of 
the pain pathway.23 Opioid receptors are present throughout 
the nervous system, and the interactions of opioids with 
nonanalgesic receptors are responsible for many of the side 
effects associated with opioid treatment.23 For example, 
opioids may induce nausea and vomiting by direct stimulation 
of receptors at the chemoreceptor trigger zone and vestibular 
apparatus.30
A systematic review31 of randomized controlled trials of 
opioids in postoperative patients found that the most common 
side effects occurring in these patients were gastrointestinal 
side effects, central nervous system (CNS) side effects, 
pruritus, and urinary retention. Pruritus occurred in 18.3% of 
patients who were treated with opioids following surgery and 
was most common with epidural administration of opioids.31 
Somnolence and sedation were the most commonly reported 
CNS side effects; the incidence of somnolence ranged from 
less than 2% to more than 90%, depending on the route of 
administration and type of opioid used.31 Gastrointestinal side 
effects, including nausea, vomiting, and constipation, were 
the most common side effects associated with opioid analge-
sia and were reported by 31.0% of patients.31 Opioid-induced 
postoperative nausea and vomiting (PONV) is associated with 
negative effects on patient outcomes and quality of life,32 
which may lead to increases in recovery time, duration of 
hospitalization, and cost of medical care.33,34 The underuse 
of opioid analgesics by health care providers to relieve acute 
pain may be related to attempts to balance analgesia against 
concerns about opioid-induced side effects and subsequent 
deleterious repercussions for patient outcomes.20
There is a continuing need for a potent analgesic agent that 
will provide adequate relief of acute pain, but with a reduction 
in side effects. Tapentadol is a novel, centrally acting analgesic 
that offers analgesic efficacy that is similar to that provided by 
a pure µ-opioid agonist comparator, but with an improved side 
effect profile, which may represent a significant advancement 
in the management of moderate to severe acute pain.
Pharmacology and 
pharmacokinetics of tapentadol
Tapentadol (Figure 1) is a centrally acting analgesic with 
2 complementary mechanisms of action, µ-opioid receptor 
agonism and norepinephrine reuptake inhibition.35,36 In opioid 
receptor binding studies, tapentadol was found to have only a 
modest affinity (dissociation constant [Ki] = 0.096 µM [rat])35 
for the µ-opioid receptor relative to pure µ-opioid receptor 
agonists such as oxycodone (Ki = 0.018 µM [rat]) or morphine 
(Ki = 0.002 µM [rat]).37 A similar binding affinity to that 
observed in native rat receptors was demonstrated for tapent-
adol at the human recombinant µ-opioid receptor (Ki = 0.16 µM 
[human]).35 Despite the approximately 50-fold difference in 
binding affinity for the µ-opioid receptor relative to morphine, 
tapentadol demonstrated only a 2- to 3-fold reduction in 
analgesic potency in a series of acute and persistent animal Journal of Pain Research 2010:3 
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pain models.36 This disparity in potency and binding affinity 
for the µ-opioid receptor may be related to the contribution of 
the second mechanism of action, inhibition of norepinephrine 
reuptake, to the analgesic effects of tapentadol. In rat synapto-
somal reuptake assays, tapentadol inhibited the norepinephrine 
reuptake transporter with a Ki of 0.48 ± 0.11 µM and, when 
administered in intraperitoneal doses of 4.64 to 10 mg/kg, 
produced a dose-dependent increase in extracellular levels of 
norepinephrine in the ventral hippocampus of freely moving 
rats to a maximum of 450% above baseline with 10 mg/kg, 
as measured by microdialysis.35 In contrast to tapentadol, 
morphine administered to rats in intraperitoneal doses of 1 to 
10 mg/kg produced a small, nonsignificant decrease in extracel-
lular norepinephrine levels.35
The contributions of both µ-opioid receptor agonism 
and norepinephrine reuptake inhibition to the analgesic 
effects of tapentadol were further elucidated by examining 
the extent to which analgesia was blocked by the selective 
µ-opioid receptor antagonist naloxone and the norepinephrine 
α2-receptor antagonist yohimbine.35 In an animal model35 
of acute (writhing) pain, it was observed that intravenous 
tapentadol and morphine induced dose-dependent inhibi-
tion of writhing (ED50 for tapentadol, 0.7 mg/kg; ED50 for 
morphine, 0.4 mg/kg). When combined with naloxone, 
the antinociceptive effect of morphine (0.681 mg/kg) was 
more potently reduced than that of tapentadol (3.16 mg/kg); 
the ED50 for naloxone antagonism was 0.007 mg/kg when 
combined with morphine and 0.099 mg/kg when combined 
with tapentadol (P  0.001 for tapentadol vs morphine). In a 
spinal nerve ligation model of mononeuropathic pain,35 coad-
ministration of intraperitoneal naloxone (0.3 mg/kg) with 
equianalgesic intravenous doses of tapentadol (10 mg/kg) or 
morphine (6.81 mg/kg) reduced the anti-allodynic effect of 
tapentadol from 72% to 42% of the maximal possible effect 
(MPE); the anti-allodynic effect of morphine was reduced 
from 83% to 25% of the MPE. In contrast, when yohimbine 
(2.15 mg/kg) was administered intraperitoneally in combi-
nation with intravenous doses of morphine (6.81 mg/kg) or 
tapentadol (10 mg/kg), the anti-allodynic effect of tapentadol 
was reduced from 81% to 19% of the MPE, whereas the anti-
allodynic effect of morphine was only minimally reduced 
(from 80% to 54% of the MPE).35 These results indicate that 
both µ-opioid receptor agonist and norepinephrine reuptake 
inhibitor mechanisms are involved in the analgesic effect of 
tapentadol and that, in contrast to morphine, norepinephrine 
reuptake inhibition plays a prominent role in tapentadol-
induced analgesia.
In addition to contributing to the analgesic activity of 
tapentadol, the opioid-sparing effect of norepinephrine reup-
take inhibition may also contribute to a reduction of adverse 
effects associated with pure µ-opioid agonists.36 Such an 
opioid-sparing effect has been achieved by combining other 
analgesics, such as NSAIDs or COX-2–specific inhibitors, 
with opioids to control acute pain.38 This type of multimodal 
strategy achieves an additive analgesic effect by combining 
2 different mechanisms of analgesic activity, but reduces the 
consumption of opioid analgesics and, thereby, the incidence 
of adverse effects associated with µ-opioid agonist activity.38 
For example, in a study of 200 patients undergoing outpatient 
anterior cruciate ligament surgery, patients who received 
perioperative doses of the COX-2–specific inhibitor celecoxib 
in addition to oxycodone experienced less pain (P  0.01) 
in the recovery room, had lower postoperative opioid con-
sumption (P  0.001), and reported a lower incidence of 
PONV (P  0.05) than patients taking oxycodone alone.39 
By combining a second mechanism of analgesic activity with 
µ-opioid receptor agonism, tapentadol may offer the benefits 
of multimodal analgesia within a single molecule.
The analgesic effects of tapentadol are independent of 
metabolic activation, and tapentadol has no active metabolites.40 
Orally administered tapentadol is principally cleared by hepatic 
glucuronidation via the uridine 5′-diphospho-glucuronosyl 
transferases (UGTs) UGT1A9 and UGT2B7, which are 
responsible for approximately 55% of tapentadol metabolism 
in humans.41 The major metabolite of tapentadol, tapentadol-
O-glucuronide, has no activity at opioid receptors, synapto-
somal reuptake systems, or other binding sites.35 Morphine is 
likewise primarily metabolized by hepatic glucuronidation via 
UGT2B7 to morphine-3-glucuronide (M3G) and morphine-
6-glucuronide (M6G).42 Morphine-3-glucuronide has no 
OH
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analgesic activity, but M6G has an affinity for the µ-opioid 
receptor and contributes significantly to the analgesic effect of 
morphine.43 In patients with renal insufficiency, M6G accumu-
lates and may contribute to the higher incidence of morphine 
toxicity observed in these patients.44,45
Many other opioids, including oxycodone, codeine, dihy-
drocodeine, hydrocodone, and tramadol, are primarily metab-
olized by the cytochrome P450 (CYP) enzymes CYP2D6 
or CYP3A4.46 Mutations in the CYP2D6 gene, which occur 
in approximately 1% to 7% of the Caucasian population, 
can either decrease or increase enzyme activity, leading to 
alterations in opioid analgesia.47 The analgesic effects of 
codeine are highly dependent on conversion of codeine to 
morphine by CYP2D6; a poor CYP2D6 metabolic phenotype 
can suppress codeine analgesia, and an ultra-rapid CYP2D6 
metabolic phenotype can lead to increased opioid effects, 
such as euphoria, dizziness, and visual disturbances.47
In addition to the potential for varied individual responses 
to cytochrome P450-metabolized opioids due to genetic 
mutations, opioids metabolized by the cytochrome P450 path-
way are associated with an increased risk for drug–drug interac-
tions. More than half of all drugs are metabolized by CYP3A4, 
and opioids metabolized by this isozyme (including fentanyl, 
buprenorphine, and methadone) are prone to drug–drug interac-
tions with antiretroviral agents and antidepressants.48 Opioids 
metabolized by CYP2D6, including codeine, dihydrocodeine, 
and oxycodone, are also associated with a number of drug–drug 
interactions. Substrates of CYP2D6 include antiarrhythmic 
agents, antidepressants, antipsychotics, antiparasitic agents, and 
tamoxifen.48 The analgesic activity of codeine is particularly 
impaired by inhibition of CYP2D6 because the analgesic effects 
of codeine result from the formation of metabolites, including 
morphine and, possibly, codeine-6-glucuronide.48
In vitro studies41 were used to evaluate the inhibitory or 
inducing effects of tapentadol on the 7 major CYP isoforms 
involved in drug metabolism (CYP2D6, CYP3A4, CYP1A2, 
CYP2A6, CYP2C9, CYP2C19, and CYP2E1). Tapentadol 
did not undergo significant metabolism by CYP enzymes 
and did not inhibit or induce the activity of any of the CYP 
isoforms tested, with the exception of CYP2D6.41 Limited 
inhibition of CYP2D6 was observed with tapentadol, with 
competitive inhibition occurring with a Ki of 181 µM and 
noncompetitive inhibition with a Ki of 1,410 µM.41 The 
Ki values for both competitive and noncompetitive inhibi-
tion are much higher than the expected tapentadol plasma 
concentrations of 0.5 to 1 µM (following therapeutic dosing), 
indicating that CYP2D6 inhibition by tapentadol is unlikely 
to be clinically relevant.41
Two randomized, open-label studies were performed to 
evaluate the potential for drug–drug interactions between 
tapentadol and 3 common analgesics that, like tapentadol, are 
metabolized by UGT pathways (acetaminophen, naproxen, and 
acetylsalicylic acid).49 Mean serum concentrations of tapent-
adol and tapentadol-O-glucuronide were similar after adminis-
tration of tapentadol IR alone and after coadministration with 
acetaminophen and acetylsalicylic acid. A slight increase in 
the serum concentration of tapentadol and a slight decrease 
in the serum concentration of tapentadol-O-glucuronide 
were observed after coadministration with naproxen, but 
these changes were not considered clinically relevant, due 
to the relatively small magnitude of change. Thus, no dosing 
adjustments are needed for administration of tapentadol with 
any of these commonly coadministered analgesics.
Tapentadol IR for moderate 
to severe pain
The efficacy of tapentadol IR for the relief of moderate to severe 
pain has been evaluated in 3 randomized, double-blind, phase 3 
studies in patients with postoperative (bunionectomy) pain50,51 
and pain related to end-stage degenerative joint disease52 and 
as a secondary measure in a phase 3 randomized, double-
blind, 90-day safety study.53 In one of the postoperative pain 
studies,51 patients received tapentadol IR (50, 75, or 100 mg), 
oxycodone HCl IR (15 mg), or placebo every 4 to 6 hours for 
72 hours following bunionectomy; in the other postoperative 
pain study,50 patients received tapentadol IR (50 or 75 mg), 
oxycodone HCl IR (10 mg), or placebo every 4 to 6 hours 
for 72 hours following bunionectomy. In the end-stage joint 
disease study,52 patients received tapentadol IR (50 or 75 mg), 
oxycodone HCl IR (10 mg), or placebo every 4 to 6 hours for 
10 days. In the 90-day safety study,53 patients received flexible 
doses of tapentadol IR 50 or 100 mg (up to 600 mg/day) or 
oxycodone HCl 10 mg or 15 mg (up to 90 mg/day) every 4 to 
6 hours as needed for up to 90 days.
In all 4 phase 3 studies50–53 of tapentadol IR for acute 
pain, improvements in pain intensity were observed with 
tapentadol IR treatment (50, 75, or 100 mg every 4 to 6 hours) 
that were similar to those observed with oxycodone HCl IR 
treatment (10 or 15 mg every 4 to 6 hours) based on pain 
intensity measurements on an 11-point numerical rating scale 
(NRS; 0 = “no pain” to 10 = “worst pain imaginable”). For 
example, in the postoperative pain study50 in which patients 
received tapentadol IR (50 or 75 mg) for 72 hours following 
bunionectomy, 901 patients were randomized to treatment. 
In that study,50 efficacy was evaluated based on the following 
measures: the sum of the pain intensity difference (SPID) over Journal of Pain Research 2010:3 
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the first 12, 24, 48 (primary efficacy endpoint), and 72 hours of 
treatment; responder rates at 48 hours; and the patient global 
impression of change (PGIC). Based on increases in the mean 
(SD) SPID48, significantly greater reductions in pain inten-
sity from baseline were observed with tapentadol IR 50 mg 
(122.2 [98.66]), tapentadol IR 75 mg (143.7 [96.52]), and 
oxycodone HCl IR 10 mg (140.3 [99.52]) than with placebo 
(54.1 [105.74]; P  0.001 for all comparisons; Figure 2). 
Additionally, the efficacy of both doses of tapentadol IR was 
noninferior to the efficacy of oxycodone HCl IR 10 mg, based 
on the lower bounds of the 2-sided 97.5% confidence inter-
vals for tapentadol IR 50 mg (−36.05) and 75 mg (−12.91), 
which were within the prespecified noninferiority margin 
of −48 (10% of the total possible value).
Secondary efficacy measurements supported the results 
of the primary efficacy endpoint in this phase 3 postoperative 
pain study.50 Compared with placebo, significant reductions 
in pain intensity (based on the SPID) were observed for all 
active treatment groups at 12, 24, and 72 hours (P  0.001 
for all comparisons; Figure 2).
The distribution of responder rates was also significantly 
different between both tapentadol IR dose groups and placebo 
(P  0.001) and oxycodone HCl IR 10 mg and placebo 
(P  0.001; Figure 3). Compared with placebo, a significantly 
greater percentage of patients in all active treatment groups 
reported reductions in pain intensity at 48 hours of at least 
30% (tapentadol IR 50 mg, 77.5%; tapentadol IR 75 mg, 
76.3%; oxycodone HCl IR 10 mg, 75.2%; placebo, 58.0%; 
P  0.004 for all comparisons) and at least 50% (tapentadol 
IR 50 mg, 64.7%; tapentadol IR 75 mg, 64.0%; oxycodone 
HCl IR 10 mg, 64.4%; placebo, 47.8%; P  0.012 for all 
comparisons).
For the PGIC, patients rated their overall status since 
beginning study medication on a 7-point scale (1 = “very 
much improved” to 7 = “very much worse”). At the end of the 
study or early discontinuation, a rating of “much improved” 
or “very much improved” on the PGIC was reported by 83% 
of patients in the tapentadol IR 50-mg group, 88% of patients 
in the tapentadol IR 75-mg group, 86% of patients in the 
oxycodone HCl IR 10-mg group, and 65% of patients in the 
placebo group. The overall distribution of PGIC scores was 
significantly more favorable for all active treatment groups 
compared with placebo (P  0.001 for all comparisons).
Safety and tolerability  
of tapentadol IR
In all 4 studies,50–53 the most commonly reported treat-
ment emergent adverse events (TEAEs) for patients who 
received any dosage of tapentadol IR were typical of drugs 
with µ-opioid agonist activity, and there were no major TEAEs 
suggestive of hyper-adrenergism. In the phase 3 study50 of 
tapentadol IR 50 and 75 mg in patients with postoperative 
pain following bunionectomy, the most common TEAEs 
(reported by 10% of patients in any treatment group) were 
nausea, vomiting, dizziness, headache, somnolence, pruritus, 
and constipation. Tapentadol IR 50 mg was associated with 
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a lower incidence of all of these TEAEs than oxycodone HCl 
IR 10 mg, and tapentadol IR 75 mg was associated with a 
lower incidence of nausea, headache, and constipation than 
oxycodone HCl IR 10 mg (Figure 4). A significantly lower 
percentage of patients reported nausea and/or vomiting in the 
tapentadol IR 50-mg group (35%) than in the oxycodone HCl 
IR 10-mg group (59%; P  0.001). Thus, at a dose (50 mg) 
that provided efficacy that was noninferior to that provided by 
oxycodone HCl IR 10 mg, tapentadol IR was associated with 
a significantly lower incidence of gastrointestinal adverse 
events than oxycodone IR. A lower percentage of patients in 
the tapentadol IR 75-mg (51%) than in the oxycodone HCl 
IR 10-mg group (59%) reported nausea and/or vomiting, 
but the difference did not reach statistical significance (P = 
0.057). A low percentage (3% in any treatment group) of 
patients reported TEAEs that led to study discontinuation 
in the tapentadol IR 50-mg group (1.1%), the tapentadol IR 
75-mg group (2.9%), the oxycodone HCl IR 10-mg group 
(1.8%), and the placebo group (1.5%).
The 90-day safety study53 permitted an evaluation of the 
long-term safety of flexible doses of tapentadol IR (50 or 
100 mg every 4 to 6 hours) in comparison with flexible doses 
of oxycodone HCl IR (10 or 15 mg every 4 to 6 hours) in 
patients with acute osteoarthritis hip or knee pain or low 
back pain. Similar to the phase 3 postoperative pain study,50 
the most common TEAEs (occurring in 10% of patients 
in either treatment group) included gastrointestinal TEAEs 
(nausea, vomiting, and constipation), nervous system TEAEs 
(dizziness, headache, and somnolence), and pruritus. A lower 
percentage of patients in the tapentadol IR group than in the 
oxycodone IR group reported nausea (18.4% vs 29.4%), 
vomiting (16.9% vs 30.0%), constipation (12.8% vs 27.1%), 
and pruritus (4.3% vs 11.8%). Odds ratios demonstrated 
that patients treated with tapentadol IR were significantly 
less likely than patients treated with oxycodone IR to report 
nausea (0.542), vomiting (0.476), the composite of nausea 
and/or vomiting (0.458), or constipation (0.396; P  0.001 
for all comparisons). In addition, a lower percentage of 
patients discontinued from the study because of AEs in the 
tapentadol IR group (20.8%) than in the oxycodone IR group 
(30.6%), and patients in the oxycodone IR group discontinued 
significantly earlier than those in the tapentadol IR group 
(nominal P  0.05; Figure 5). The percentage of patients 
who discontinued from the study due to gastrointestinal 
AEs was lower in the tapentadol IR group (8.8%) than in 
the oxycodone IR group (21.1%).
Compared with placebo, tapentadol IR (50 to 100 mg 
every 4 to 6 hours) and oxycodone HCl IR (10 or 15 mg 
every 4 to 6 hours) were associated with a higher incidence 
of TEAEs at all doses studied, and the majority of TEAEs 
increased with increasing dose.50–52 However, tapentadol 
IR was associated with a reduction in TEAEs, particularly 
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Figure  The distribution of times to discontinuation due to adverse events from the 90-day safety study among patients with osteoarthritis hip or knee pain or low back 
pain treated with tapentadol iR or oxycodone iR. Reproduced from Hale et al (2009).53
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gastrointestinal TEAEs and pruritus, relative to oxycodone 
IR in all 4 phase 3 studies.50–53 The lower incidence of gas-
trointestinal TEAEs observed with tapentadol IR relative to 
oxycodone IR50–53 was associated with a lower percentage 
of patients who discontinued treatment because of TEAEs. 
Nausea and vomiting are often associated with the initiation 
of opioid therapy27 and are considered to be among the most 
undesirable adverse effects associated with analgesic therapy.54 
These opioid-induced gastrointestinal TEAEs may be dose-
limiting and are often severe enough to cause patients to dis-
continue therapy, leading to disruption of pain relief.55,56
Conclusions
Tapentadol is a novel, centrally acting analgesic with 
2 mechanisms of action, µ-opioid receptor agonism and 
norepinephrine reuptake inhibition,35,36 which may contribute 
to an improved gastrointestinal tolerability profile. In patients 
with moderate to severe acute pain of various etiologies, 
tapentadol IR has been shown to offer comparable analgesia 
to that provided by oxycodone IR, with lower incidences of 
gastrointestinal adverse effects and pruritus and lower rates of 
discontinuation due to adverse effects.50–53 This combination 
of potent analgesia and tolerability may represent a substan-
tial improvement over current acute pain relief strategies.
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